"13" . "1386-341X" . . . . "Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension" . "11"^^ . "V" . . "Melmed, Shlomo" . . "Lam, Karen, S., L." . "Goth, Miklos, I." . "Pituitary" . "RIV/00064165:_____/10:6437" . . "283909" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "RIV/00064165:_____/10:6437!RIV11-MZ0-00064165" . "[EFE133E6236E]" . "000273685600003" . . "1" . . "Schopohl, Jochen" . "1"^^ . . . "Cook, David" . "Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension" . "Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension"@en . "Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension"@en . . . "Treatment of acromegaly; lanreotide Autogel therapy; insulin-like growth factor-1; growth hormone"@en . "The study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release Autogel formulation of the somatostatin analogue lanreotide (Lan-Autogel) in unselected patients with acromegaly. The study comprised four phases: washout; a double-blind comparison with placebo, at a single randomized dose (60, 90 or 120 mg) of Lan-Autogel; a single-blind, fixed-dose phase for four injections (placebo group was re-allocated to active treatment); and eight injections with doses tailored according to biochemical response. Serum samples were assessed for growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, at weeks 4, 13, 14, 15, 16, 32 and 52. 108 patients were enrolled and 99 completed 52 weeks' treatment." . "Marek, Josef" . "6"^^ . . . "The study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release Autogel formulation of the somatostatin analogue lanreotide (Lan-Autogel) in unselected patients with acromegaly. The study comprised four phases: washout; a double-blind comparison with placebo, at a single randomized dose (60, 90 or 120 mg) of Lan-Autogel; a single-blind, fixed-dose phase for four injections (placebo group was re-allocated to active treatment); and eight injections with doses tailored according to biochemical response. Serum samples were assessed for growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, at weeks 4, 13, 14, 15, 16, 32 and 52. 108 patients were enrolled and 99 completed 52 weeks' treatment."@en . .